Guselkumab for Inflammatory Bowel Disease with Joint Pain
Treatments studied
Part of Bones, joints & muscles, Digestive system clinical trials.
This trial tests whether guselkumab, a newer biologic medication, can treat people who have both inflammatory bowel disease (Crohn's disease or ulcerative colitis) and spondyloarthritis (joint inflammation and pain). Researchers want to see if this one drug can help both conditions at the same time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of Crohn's disease or ulcerative colitis by colonoscopy with tissue samples (or MRI if only small intestine affected)
- Age 18–75 years old
- Planning to start guselkumab treatment within the next 30 days
- Never received IL-23 inhibitor drugs before (such as mirikizumab or ustekinumab)
- No active or recent tuberculosis (TB) infection or treatment
- Not currently pregnant or planning pregnancy during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
Hear when a new Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.